PMID: 7527244Aug 1, 1994Paper

Peripheral blood stem cells (PBSCs) collected after recombinant granulocyte colony stimulating factor (rhG-CSF): an analysis of factors correlating with the tempo of engraftment after transplantation

British Journal of Haematology
W I BensingerJ Klarnet

Abstract

Factors affecting mobilization and engraftment were analysed in 54 patients undergoing transplant using autologous PBSCs mobilized with high-dose recombinant granulocyte stimulating factor (rhG-CSF). Patients received 5-7 d of rhG-CSF, 16 micrograms/kg/d, administered subcutaneously. PBSCs were harvested by leukapheresis using automated continuous-flow blood cell separators beginning on day 4 of rhG-CSF, processing 10 litres of whole blood, for 2-6 consecutive days. Transplants were performed for the following diseases: breast cancer (n = 22), non-Hodgkin's lymphoma (n = 18), multiple myeloma (n = 7) and other (n = 7). Engraftment was rapid with patients reaching a neutrophil count of 1 x 10(9)/l a median of 12 d (range 9-22) after transplant. Platelets > 20 x 10(9)/l independent of transfusion support were achieved a median of day 10 (range 7-60) after infusion. Multiple factors potentially influencing engraftment were examined using a Cox regression model. The number of CD34+ cells per kg was highly correlated with the time to achievement of granulocyte and platelet recovery (P < 0.012, 0.0001). The use of a post-infusion growth factor and a radiation preparative regimen was important for neutrophil recovery, and a diagnosis ...Continue Reading

References

Jul 1, 1987·British Journal of Haematology·L B To, C A Juttner
Jan 1, 1993·Journal of Hematotherapy·R HaasW Hunstein
Aug 1, 1993·Diabetes Research and Clinical Practice·Y KawaguchiT Ogihara

❮ Previous
Next ❯

Citations

Dec 1, 1995·Stem Cells·W I BensingerC D Buckner
Jul 24, 2008·Bone Marrow Transplantation·R LadensteinUNKNOWN EBMT Paediatric Working Party
Jun 5, 2012·Bone Marrow Transplantation·L J FernyhoughB D Hock
Jan 1, 1997·Vox Sanguinis·M J Watts, D C Linch
Nov 9, 2002·Therapeutic Apheresis : Official Journal of the International Society for Apheresis and the Japanese Society for Apheresis·Taner DemirerHamdi Akan
May 23, 2007·The Journal of Experimental Medicine·Kuen-Jer TsaiChe-Kun James Shen
Jun 1, 1999·Journal of Hematotherapy·T DemirerC D Buckner
Oct 25, 2002·Cancer Biotherapy & Radiopharmaceuticals·Ivan Aksentijevich, Ian Flinn
Mar 30, 2000·Journal of Hematotherapy & Stem Cell Research·M J AlcornT Holyoake
Feb 15, 2001·Journal of Hematotherapy & Stem Cell Research·D R FlemingR H Herzig
May 2, 2002·Journal of Hematotherapy & Stem Cell Research·Kenneth R MeehanMarc E Lippman

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

B-Cell Lymphoma

B-cell lymphomas include lymphomas that affect B cells. This subtype of cancer accounts for over 80% of non-Hodgkin lymphomas in the US. Here is the latest research.